| |
Shimadzu Biotech will be presenting a lunctime seminar
Lunchtime Seminars - March 5th
| 12:00 - 1:30 |
- |
"Applications of true high-energy CID MS/MS in the identification of proteins, peptides, and biological molecules in complex samples" |
|
|
(Joseph Fox, Ph.D. Shimadzu Corporation) |
| |
|
|
"Intact Protein based Analysis System (IPAS) and its application in Cancer Proteomics" |
|
|
(Hong Wang, Ph.D. Fred Hutchinson Cancer Research Center) |
Dr. Rachel Martin, Shimadzu Biotech UK Applications Manager and Dr. Fan Xiang, US Applications Senior Scientist, will be teaching sections in the "Tandem Mass Spectrometry Methods for Proteomics" short course being held on March 4, 2007
9am - 4pm
|
- |
This course will introduce the basic principles of tandem mass spectrometry, fragmentation methods and the different kinds of instruments commonly used in proteomics. Triple quadrupoles, quadrupole and linear ion traps, Fourier transform mass spectrometers, tandem TOFs and several hybrid configurations provide different analytical advantages for amino acid sequencing, for determining post-translational modifications, and for multiple reaction monitoring. The course will describe the most common fragmentation methods, CID, IRMPD, ECD and ETD, how they differ in the fragmentation information they provide, and how they are used in top-down and bottom-up strategies. It will describe the basic fragmentation nomenclature and what is known about the mechanisms of CID that lead to the formation of b and y ions, while electron transfer favors c and z ions. Specific applications in biological research will illustrate the use of these techniques for amino acid sequencing and for the determination of phosphorylation sites, glycsolyation, acetylation and ubiquitylation. The course will also cover methods for searching sequence databases, de novo sequencing, quantitative proteomics, isotope labeling strategies, and chemically assisted fragmentation.
Tuition: $150.00 |
|
|
(Instructors: Fan Xiang, Shimadzu Corporation; Robert J. Cotter, Johns Hopkins School of Medicine; Ron Beavis, University of British Columbia; David Goodlett, University of Washington; and Rachel Martin, Shimadzu Biotech (UK).) |
|
|
| |
|
|
| Sorry, this page cannot be emailed. |
|
|
|
 |
| |
|
|
| Sorry, there is no print-friendly version of this page. Please click OK to use your browser's normal print function. |
| |
|
|
|
|
|
|
